Grant: CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
University of Alberta
$67,500.00
Identifying anatomical site-specific drivers of antitumor immunity in cancer
EF 2024-25
Résumé
RATIONALE. Different types of cancer have very different molecular features and clinical outcomes for reasons that remain poorly
understood. Microsatellite instability (MSI) arises in some cancers when DNA mismatch repair fails, typically due to loss of MLH1.
The frequency of MSI varies considerably in different types of cancer and is highest in endometrial cancer (EC) (˜25%) and colorectal
cancer (CRC) (˜15%). Notably, MSI in CRC and EC is associated with a better patient prognosis and higher infiltration by CD8+ tumor
infiltrating lymphocytes (TILs) than their non-MSI counterparts. This is most commonly attributed to the genome-wide point
mutations that accumulate in MSI cancers and generate abundant neoantigens that can be recognized by tumor specific TILs. This
explanation is consistent with the high response rate of MSI cancers to immune checkpoint inhibitors (ICI) such as anti-PD1 but fails
to explain several important observations. First, improved immunogenicity is only seen in early stage MSI EC and CRC while patients
with advanced stage III and IV MSI disease do not have superior survival despite their high mutation rate. Second, MSI in most
cancer types (especially breast and lung cancer) is associated with a worse prognosis and poorer inherent antitumor immune
response despite having similar mutation loads to EC and CRC. Third, MSI cancers in different anatomical sites carry distinct gene
expression patterns and secondary oncogenic mutations. These observations suggest that the immunogenicity of an MSI cancer
depends in part on site-specific selective pressures and tissue specific factors that determine immune activation in response to
endogenously arising changes in the tumor cells.
A critical challenge remaining in the cancer field is determining the role of the tumor microenvironment (TME) in cancer
development and progression. Resolving this question is difficult due to the variability in both endogenous oncogenic features in the
cancer cells and infiltrating immune cells in the TME. In addition, the unique resident immune cells in each tissue will set a different
baseline level of immune activation that contributes to the TME of different cancers. Given their common underlying mechanism
but divergent immunogenicity, MSI cancers from different anatomical sites offer a unique opportunity to dissect apart the role of
tissue-specific TME factors from tumor-specific endogenous factors in governing the immunogenicity of different cancer types. This
could provide important information about how to maximize the efficacy of immunotherapy for different MSI and non-MSI cancer
types throughout the body.
RESEARCH GOAL & AIMS. Our overall goal is to determine to what extent the phenotype of MSI cancers in different locations is
determined by local site-specific immune dynamics versus endogenous tumor cell properties.
Aim 1. Determine how the overall immune profile of MSI cancers varies across tissue sites. To determine how the local tissue
environment governs the immunogenicity and prognosis of MSI cancers in specific sites, we have created MSI versions of colorectal
cancer, non-small cell lung cancer and breast cancer cell lines by deleting MLH1. We will orthotopically implant the MSI and non-MSI
version of each of these cancer types in the three relevant anatomical sites (colon, lung and mammary fat pad) and will compare the
growth and immune profile of each tumor in each location using high dimensional flow cytometry and spatial transcriptomics. We
will also compare the immune profiles between the different MSI tumor types at each location. Finally, we will identify the tissuespecific
factors most relevant to human MSI cancers using organoid coculture models and immune cell preconditioning with tissuespecific
factors. This will allow us to determine the relative importance of tissue location compared to tumor type in determining
immunogenicity.
Programme
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
537940
Name
Baker Kristi
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Identifying anatomical site-specific drivers of antitumor immunity in cancer
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Res. Grants - Breast Cancer
Keyworddelim
Cancer
Abstract
RATIONALE. Different types of cancer have very different molecular features and clinical outcomes for reasons that remain poorly
understood. Microsatellite instability (MSI) arises in some cancers when DNA mismatch repair fails, typically due to loss of MLH1.
The frequency of MSI varies considerably in different types of cancer and is highest in endometrial cancer (EC) (˜25%) and colorectal
cancer (CRC) (˜15%). Notably, MSI in CRC and EC is associated with a better patient prognosis and higher infiltration by CD8+ tumor
infiltrating lymphocytes (TILs) than their non-MSI counterparts. This is most commonly attributed to the genome-wide point
mutations that accumulate in MSI cancers and generate abundant neoantigens that can be recognized by tumor specific TILs. This
explanation is consistent with the high response rate of MSI cancers to immune checkpoint inhibitors (ICI) such as anti-PD1 but fails
to explain several important observations. First, improved immunogenicity is only seen in early stage MSI EC and CRC while patients
with advanced stage III and IV MSI disease do not have superior survival despite their high mutation rate. Second, MSI in most
cancer types (especially breast and lung cancer) is associated with a worse prognosis and poorer inherent antitumor immune
response despite having similar mutation loads to EC and CRC. Third, MSI cancers in different anatomical sites carry distinct gene
expression patterns and secondary oncogenic mutations. These observations suggest that the immunogenicity of an MSI cancer
depends in part on site-specific selective pressures and tissue specific factors that determine immune activation in response to
endogenously arising changes in the tumor cells.
A critical challenge remaining in the cancer field is determining the role of the tumor microenvironment (TME) in cancer
development and progression. Resolving this question is difficult due to the variability in both endogenous oncogenic features in the
cancer cells and infiltrating immune cells in the TME. In addition, the unique resident immune cells in each tissue will set a different
baseline level of immune activation that contributes to the TME of different cancers. Given their common underlying mechanism
but divergent immunogenicity, MSI cancers from different anatomical sites offer a unique opportunity to dissect apart the role of
tissue-specific TME factors from tumor-specific endogenous factors in governing the immunogenicity of different cancer types. This
could provide important information about how to maximize the efficacy of immunotherapy for different MSI and non-MSI cancer
types throughout the body.
RESEARCH GOAL & AIMS. Our overall goal is to determine to what extent the phenotype of MSI cancers in different locations is
determined by local site-specific immune dynamics versus endogenous tumor cell properties.
Aim 1. Determine how the overall immune profile of MSI cancers varies across tissue sites. To determine how the local tissue
environment governs the immunogenicity and prognosis of MSI cancers in specific sites, we have created MSI versions of colorectal
cancer, non-small cell lung cancer and breast cancer cell lines by deleting MLH1. We will orthotopically implant the MSI and non-MSI
version of each of these cancer types in the three relevant anatomical sites (colon, lung and mammary fat pad) and will compare the
growth and immune profile of each tumor in each location using high dimensional flow cytometry and spatial transcriptomics. We
will also compare the immune profiles between the different MSI tumor types at each location. Finally, we will identify the tissuespecific
factors most relevant to human MSI cancers using organoid coculture models and immune cell preconditioning with tissuespecific
factors. This will allow us to determine the relative importance of tissue location compared to tumor type in determining
immunogenicity.
Competitiondate
202502
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Baker, Kristi
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $67,500~ $0~